Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Disorders of Erythrocytes

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

3D Measurement of Chronic Wounds in Routine Care: A Review with Practical Guidance for Smartphone Photogrammetry.

Annals of biomedical engineering·2026

Same author

A strategy for distant kinship analysis using historical human remains: First identifications of Stalinist terror victims in Adjara, Georgia.

Forensic science international. Genetics·2026

Same author

Clinical relevance of tissue copper, selenium, and cadmium alterations in colorectal cancer.

Scientific reports·2026

Same author

When CBCT Looks Borderline and Standard Radiology Is Inconclusive: Should We Plate or Should We Wait?

Diagnostics (Basel, Switzerland)·2025

Same author

Abnormalities in Pulmonary Function Tests in Patients with Psoriasis.

Dermatology (Basel, Switzerland)·2025

Same author

High performance eco-friendly free abrasive machining using an additively fabricated tool and PCD based slurry.

Scientific reports·2025

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

[Pancytopenia after methotrexate treatment].

Krzysztof Zak¹, Andrzej Prystupa, Andrzej Dybała

¹Katedra i Klinika Chorób Wewnetrznych Uniwersytetu Medycznego w Lublinie, Samodzielny Szpital Kliniczny Nr 1 w Lublinie.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)

|February 10, 2010

Summary

Methotrexate (MTX) can cause severe side effects. A patient developed acute liver failure and bone marrow damage due to non-compliant MTX therapy, leading to death.

Related Experiment Videos

Last Updated: Jun 16, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Area of Science:

Rheumatology
Toxicology
Hepatology

Background:

Methotrexate (MTX) is a widely used medication for various conditions, including inflammatory joint diseases.
MTX therapy is associated with a spectrum of potential adverse effects, ranging in severity.
Patient adherence to prescribed treatment regimens is crucial for therapeutic efficacy and safety.

Observation:

A 76-year-old female patient was undergoing outpatient treatment with methotrexate for vertebral joint disease of unclear origin.
The patient's therapeutic approach deviated from the recommended medical guidelines.
The patient subsequently presented with acute liver failure and signs of bone marrow suppression.

Findings:

Non-adherence to methotrexate treatment recommendations precipitated severe adverse events.
The patient experienced critical complications including acute liver failure and bone marrow damage.
Despite aggressive medical intervention and hospitalization, the patient's condition proved fatal.

Implications:

This case highlights the critical importance of patient compliance in methotrexate therapy.
Physicians must carefully monitor patients for methotrexate toxicity, especially in cases of non-adherence.
Understanding the risks associated with methotrexate is vital for managing patients with joint diseases.